Human monocytes/macrophages release TNF-α in response to Ox-LDL

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 12, 1996, Pages 1573-1579

  Jovinge, Stefan ^a   Ares, Mikko P S ^a   Kallin, Bengt ^a   Nilsson, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

AP 1; atherosclerosis; oxidized LDL; smooth muscle cells; tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATHEROGENESIS; CELL PROLIFERATION; DOSE RESPONSE; GROWTH STIMULATION; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; LIPID PEROXIDATION; LIPOPROTEIN METABOLISM; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN SECRETION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 0030482498     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.12.1573     Document Type: Article

References (50)

1. Gofman JW, Delalla O, Glazier F, Freeman NK, Lindgren FT, Nichols AV, Strisower B, Tamplin AA. The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis and coronary heart disease. Plasma. 1954;2:412-484.
2. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA. 1987; 257:2176-2180.
3. Kanell WB, Neaton JD, Wentworth D. Overall coronary heart disease mortality rates in relation to major risk factors in 325 348 men screened for the MRFIT. Am Heart J. 1986;112:825-836.
4. Steinberg D, Witztum JL. Lipoproteins and atherogenesis. JAMA. 1990;264:3047-3052.
5. Rosenfeld ME, Palinski W, Ylä-Herttuala S, Carew TE. Macrophages, endothelial cells, and lipoprotein oxidation in the pathogenesis of atherosclerosis. Toxicol Pathol. 1990;18:560-571.
6. Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits, II: selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis. 1989;9:908-918.
7. Schwenke D, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits, I: focal increases in arterial LDL concentration precede development of fatty streak lesions. Arteriosclerosis. 1989; 9:895-907.
8. Gerrity RG. The role of the monocyte in atherogenesis, I: transition of blood borne monocytes into foam cells in fatty lesions. Am J Pathol. 1981;103:181-190.
9. Joris I, Zabd T, Nunnari JJ, Krolikowski FJ, Majno G. Studies on the pathogenesis of atherosclerosis, I: adhesion and emigration of mononuclear cells in the aorta of hypercholesterolemic rats. Am J Pathol. 1983;113:341-358.
10. Faggiotto A, Ross R, Harker L. Studies of hypercholesterolemia in the nonhuman primate, I: changes that lead to fatty streak formation. Arteriosclerosis. 1984;4:323-340.
11. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
12. Steinbrecher UP, Zhang H, Lougheed M. Role of oxidatively modified LDL in atherosclerosis. Free Radic Biol Med. 1990;9:155-168.
13. 1 macrophages exposed to oxidised low-density lipoprotein. FEBS Lett. 1993;332:218-220.
14. Frostegård J, Haegerstrand A, Gidlund M, Nilsson J. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis. 1991;90:119-126.
15. Frostegård J, Wu R, Giscombe R, Holm G, Lefvert AK, Nilsson J. Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler Thromb. 1992;12:461-467.
16. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A. 1990;87:5134-5138.
17. Faggiotto A, Ross R. Studies of hypercholesterolemia in the nonhuman primate, II: fatty streak conversion of fibrous plaque. Arteriosclerosis. 1984;4:341-356.
18. Ross R, Masuda J, Raines EW, Gown AM, Katsuda S, Sasahara M, Maiden LT, Masuko H, Sato H. Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science. 1990;248: 1009-1012.
19. Martinet Y, Bitterman PB, Mornex J-F, Grotendorst GR, Martin GR, Crystal RG. Activated human monocytes express the c-sis proto-oncogene and release a mediator showing a PDGF-like activity. Nature. 1986;319:158-160.
20. Craig TE, Jackson RL, Ohlweiler DF, Ku G. Multiple lipid oxidation products in low density lipoproteins induce interleukin-1 beta release from human blood mononuclear cells. J Lipid Res. 1994;35:417-427.
21. Maeda M, Knowles RD, Kleinerman ES. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro. Cancer Commun. 1991;3:313-321.
22. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science. 1991;251:936-939.
23. Hamilton TA, Ma G, Chisolm GM. Oxidized low density lipoprotein suppresses the expression of tumor necrosis factor-α mRNA in stimulated murine peritoneal macrophages. J Immunol. 1990;144: 2343-2350.
24. Malden LT, Chait A, Raines EW, Ross R. The influence of oxidatively modified low density lipoproteins on expression of platelet-derived growth factor by human monocyte-derived macrophages. J Biol Chem. 1991;266:13901-13907.
25. Redgrave TG, Carlsson LA. Changes in plasma very low density and low density lipoprotein content, composition, and size after a fatty meal in normo- and hypertriglyceridemic man. J Lipid Res. 1979; 20:217-229.
26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
27. Basu SK, Goldstein JL, Anderson RGW, Brown MS. Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc Natl Acad Sci U S A. 1976;73:3178-3182.
28. Gown AM, Vogel AM, Gordon D, Lu PL. A smooth muscle-specific monoclonal antibody recognizes smooth muscle actin isozymes. J Cell Biol. 1985;100:807-813.
29. Bøyum A, et al. Isolation of lymphocytes, granulocytes and macrophages. Scand J Immunol. 1976;5(suppl 5):9-15.
30. Nilsson J, Thyberg J. Fine structure of arterial smooth muscle cells cultured in the presence of whole blood serum or plasma-derived serum. Cell Tissue Res. 1982;223:87-99.
31. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochem J. 1979;18:5294-5299.
32. Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, Dinarello CA. Nucleotide sequence of human monocyte interleukin 1 precursor DNA. Proc Natl Acad Sci U S A. 1984;81: 7907-7911.
33. Clinton SK, Fleet JC, Loppnow H, Salomon RN, Clark BD, Cannon JG, Shaw AR, Dinarello CA, Libby P. Interleukin-1 gene expression in rabbit vascular tissue in vivo. Am J Pathol. 1991; 138:1005-1014.
34. Alksnis M, Barkhem T, Strömstedt P-E, Ahola H, Kutoh E, Gustavsson J-Å, Pellinger L, Nilsson S. High level expression of functional full length and truncated glucocorticoid receptor in Chinese hamster ovary cells. J Biol Chem. 1991;266:10078-10085.
35. Schütze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K, Krönke M. TNF activates NFκB by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell. 1992;71:765-776.
36. Parthasarathy S, Printz DJ, Boyd D, Joy L, Steinberg D. Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor. Arterioscler Thromb. 1986;6: 505-510.
37. Terkeltaub R, Banka CL, Solan J, Santoro D, Brand K, Curtiss LK. Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler Thromb. 1994;14:47-53.
38. Stiko-Rahm A, Hultgårdh-Nilsson A, Regnström J, Hamsten A, Nilsson J. Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells. Arterioscler Thromb. 1992;12:1099-1109.
39. Fong LG, Fong TAT, Cooper AD. Inhibition of lipopolysaccharide-induced interleukin-1 beta messenger RNA expression in mouse macrophages by oxidized low density lipoprotein. J Lipid Res. 1991; 32:1899-1910.
40. Stiko A, Regnström J, Shah PK, Cercek B, Nilsson J. Active oxygen species and lysophosphatidylcholine are involved in oxidized low density lipoprotein activation of smooth muscle cell DNA synthesis. Arterioscler Thromb Vasc Biol. 1996;16:194-200.
41. Nakano T, Raines EW, Abraham JA, Klagsbrun M, Ross R. Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes. Proc Natl Acad Sci U S A. 1994;91:1069-1073.
42. Fuhlbrigge RC, Chaplin DD, Kiely J-M, Unanue ER. Regulation of interleukin 1 gene expression by adherence and lipopolysaccharide. J Immunol. 1987;138:3799-3802.
43. Ylä-Herttuala S, Rosenfeld ME, Parthasarathy S, Sigal E, Särkioja T, Witztum JL, Steinberg D. Gene expression in macrophage-rich human atherosclerotic lesions. J Clin Invest. 1991;87:1146-1152.
44. Tipping PG, Hancock WW. Production of tumor necrosis factor and interleukin-1 by macrophages from human atheromatous plaques. Am J Pathol. 1993;142:1721-1728.
45. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Tumor necrosis factor gene expression in human vascular intimal smooth muscle cells detected by in situ hybridization. Am J Pathol. 1990;137:503-509.
46. Takashiba S, Shapira L, Amar S, Van Dyke TE. Cloning and characterization of human TNFα promoter region. Gene. 1993;131: 307-308.
47. Rhoades KL, Golub SA, Economou JS. The regulation of the human tumor necrosis factor α promoter region in macrophages, T cell and B cell lines. J Biol Chem. 1992;267:22102-22107.
48. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J. 1991;10:2247-2258.
49. Devary Y, Gottlieb RA, Lau LF, Karin M. Rapid and preferential activation of the c-jun gene during mammalian UV response. Mol Cell Biol. 1991;11:2804-2811.
50. Ares MPS, Kallin B, Eriksson P, Nilsson J. Oxidized LDL induces transcription factor AP-1 but inhibits activation of NF-κB in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1995; 15:1584-1590.